Casdin Capital 13F holdings, Q3 2019
Holdings as of September 30, 2019 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 33 US equity positions worth $966.3m in its Q3 2019 13F filing. The largest position was SPARK THERAPEUTICS INC at 8.7% of the reported book, followed by INVITAE CORP and CDXS. Against the Q2 2019 filing, it opened 2 new positions, added to 11 and reduced 6 among the top 33 holdings.
What did Casdin Capital own in Q3 2019? Top 33 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2019 |
|---|---|---|---|---|---|---|---|
| 1 | SPARK THERAPEUTICS INC | 8.7% | $83.7m | 863,300 | -2% | reduced | |
| 2 | INVITAE CORP | 7.7% | $74.0m | 3,838,388 | 0% | held | |
| 3 | CDXS CODEXIS INC | Healthcare | 7.2% | $69.6m | 5,073,780 | 0% | held |
| 4 | 2655787D BLUEPRINT MEDICINES CORP | 7.1% | $69.1m | 940,000 | 0% | held | |
| 5 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 6.9% | $66.3m | 880,000 | 163% | added |
| 6 | MYOKARDIA INC | 6.0% | $58.1m | 1,115,000 | -13% | reduced | |
| 7 | BLUEBIRD BIO INC | 5.8% | $56.2m | 612,500 | 64% | added | |
| 8 | SG7 SAGE THERAPEUTICS INC | 5.8% | $56.1m | 400,000 | 0% | held | |
| 9 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 5.0% | $48.3m | 600,000 | -8% | reduced |
| 10 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 4.2% | $40.4m | 2,428,571 | 0% | held |
| 11 | FATE FATE THERAPEUTICS INC | Healthcare | 4.1% | $39.6m | 2,550,000 | 0% | held |
| 12 | MAGENTA THERAPEUTICS INC | 3.2% | $31.3m | 3,048,121 | 1% | added | |
| 13 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 3.1% | $30.3m | 935,000 | 89% | added |
| 14 | AUDENTES THERAPEUTICS INC | 2.5% | $24.2m | 860,000 | -11% | reduced | |
| 15 | CDNA CAREDX INC | Healthcare | 2.3% | $22.6m | 1,000,000 | 400% | added |
| 16 | GNMK GENMARK DIAGNOSTICS INC | 2.1% | $20.4m | 3,365,000 | 0% | held | |
| 17 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 2.0% | $19.4m | 1,128,075 | 0% | held |
| 18 | ILMN ILLUMINA INC | Healthcare | 1.9% | $18.3m | 60,000 | 0% | held |
| 19 | 2JQ GRITSTONE ONCOLOGY INC | 1.6% | $15.3m | 1,770,000 | 0% | held | |
| 20 | HOMOLOGY MEDICINES INC | 1.5% | $14.8m | 820,000 | 10% | added | |
| 21 | GLOBAL BLOOD THERAPEUTICS IN | 1.5% | $14.6m | 300,000 | 0% | held | |
| 22 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 1.5% | $14.3m | 463,125 | 0% | held |
| 23 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 1.4% | $13.2m | 1,455,000 | -5% | reduced |
| 24 | ALEC ALECTOR INC | Healthcare | 1.2% | $11.7m | 811,039 | 47% | added |
| 25 | DNLI DENALI THERAPEUTICS INC | Healthcare | 1.0% | $10.0m | 650,000 | 62% | added |
| 26 | CNST CONSTELLATION PHARMCETICLS I | 1.0% | $9.8m | 1,523,960 | 0% | held | |
| 27 | EDIT EDITAS MEDICINE INC | Healthcare | 1.0% | $9.4m | 415,000 | -14% | reduced |
| 28 | TWST TWIST BIOSCIENCE CORP | Healthcare | 0.7% | $7.2m | 300,000 | 0% | held |
| 29 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.6% | $5.6m | 844,285 | – | new |
| 30 | ORCHARD THERAPEUTICS PLC | 0.4% | $3.7m | 310,000 | 210% | added | |
| 31 | DECIPHERA PHARMACEUTICALS IN | 0.4% | $3.4m | 100,000 | – | new | |
| 32 | TURNING POINT THERAPEUTICS I | 0.3% | $2.8m | 75,000 | 25% | added | |
| 33 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.3% | $2.8m | 130,000 | 53% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.